For more than a decade, PCPC and its member companies worked diligently with a bipartisan group of congressional leaders and a diverse group of stakeholders to enhance the effectiveness of the U.S. Food and Drug Administration’s (FDA) regulatory authority and to provide the safety reassurances that consumers expect and deserve. As part of its ongoing commitment to cosmetics reform, PCPC and its members supported a set of Board-approved principles that have guided industry’s advocacy efforts, many of which mirror protections applied to other FDA-regulated products. 

On Dec. 29, 2022, President Biden signed into law the Consolidated Appropriations Act 2023, which includes the Modernization of Cosmetics Regulation Act (MoCRA) of 2022. This long-awaited, historic legislation gives the FDA additional tools to ensure the safety of cosmetics and to protect public health, reinforcing consumer confidence in the products they trust and enjoy every day. MoCRA also brings the FDA’s oversight of the beauty and personal care sector more in line with other categories the Agency regulates and contributes to global regulatory alignment.

While several legislative proposals emerged over the years, MoCRA was a truly bipartisan effort that brought together a diverse group of stakeholders who gathered in the spirit of collaboration and compromise to advance science-based reforms.

PCPC is providing the FDA with industry’s perspective as the Agency develops implementing regulations, anticipating member and key stakeholder needs, and assisting member companies throughout the process.

Latest Update: FDA publishes Draft Guidance on MoCRA Registration and Listing of Cosmetic Product Facilities and Products